Association ofCYP2C19*2and associated haplotypes with lower norendoxifen concentrations in tamoxifen‐treatedAsianbreast cancer patients

Authors:

Abstract
Aim: The aim was to examine the influence ofCYP2C19variants and associated haplotypes on the disposition of tamoxifen and its metabolites, particularly norendoxifen (NorEND), inAsianpatients with breast cancer.Methods: Sixty‐sixCYP2C19polymorphisms were identified in healthy Asians (n = 240), of which 14 were found to be tightly linked withCYP2C19*2,CYP2C19*3andCYP2C19*17. These 17 SNPs were further genotyped inAsianbreast cancer patients receiving tamoxifen (n = 201). Steady‐state concentrations of tamoxifen and its metabolites were quantified using liquid chromatography–mass spectrometry. Non‐parametric tests and regression methods were implemented to evaluate genotypic–phenotypic associations and haplotypic effects of the SNPs.Results: CYP2C19functional polymorphisms and their linked SNPs were not significantly associated with plasma concentrations of tamoxifen and its main metabolites N‐desmethyltamoxifen, (Z)‐4‐hydroxytamoxifen and (Z)‐Endoxifen. However,CYP2C19*2and its seven linked SNPs were significantly associated with lower NorEND concentrations, MRNorEND/NDDMand MRNorEND/(Z)‐END. Specifically, patients carrying theCYP2C19*2variant allele A had significantly lower NorEND concentrations [median (range), GGvs. GAvs. AA: 1.51 (0.38–3.28)vs. 1.28 (0.30–3.36)vs. 1.15 ng ml−1(0.26–2.45,P = 0.010)] as well as significantly lower MRNorEND/(Z)‐END[GGvs. GAvs. AA: 9.40 (3.27–28.35)vs. 8.15 (2.67–18.9)vs. 6.06 (4.47–14.6),P < 0.0001] and MRNorEND/NDDM[GGvs. GAvs.AA: 2.75 (0.62–6.26)vs.2.43 (0.96–4.18)vs.1.75 (1.10–2.49),P < 0.00001].CYP2C19H2 haplotype, which includedCYP2C19*2, was also significantly associated with lower NorEND concentrations (P = 0.0020), MRNorEND/NDDM(P < 0.0001) and MRNorEND/(Z)‐END(P < 0.0001), indicating significantly lower formation rates of NorEND.Conclusion: These data highlight the potential relevance ofCYP2C19pharmacogenetics in influencing NorEND concentrations in tamoxifen‐treated patients, which may influence treatment outcomes.

This publication has 42 references indexed in Scilit: